Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 2, 2014, Pages 1136-1145

  Gane, Edward J ^a   Rouzier, Régine ^b   Wiercinska Drapalo, Alicja ^c   Larrey, Dominique G ^d   Morcos, Peter N ^e   Brennan, Barbara J ^e   Le Pogam, Sophie ^e   Nájera, Isabel ^e   Petric, Rosemary ^e,g   Tran, Jonathan Q ^e,h   Kulkarni, Rohit ^f,i   Zhang, Ying ^f,j   Smith, Patrick ^e,k   Yetzer, Ellen S ^f   Shulman, Nancy S ^f,l  

^a Auckland Clinical Studies   (New Zealand)

^b Phase I/II Center   (France)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d HÔPITAL SAINT ELOI   (France)

^e HOFFMANN LA ROCHE INC   (United States)

^f GENENTECH INC   (United States)

^g CELGENE CORPORATION   (United States)

^h BIOGEN   (United States)

ⁱ Guardian Analytics   (United States)

^j Yingstat Consulting LLC   (United States)

^k D3 Medicine   (United States)

^l ABBVIE INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; DANOPREVIR; HEMOGLOBIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; RITONAVIR; VIRUS RNA;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BRONCHITIS; CELLULITIS; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; CRYOGLOBULINEMIA; DEPRESSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FORMICATION; HEADACHE; HEMORRHOID; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HYPOTHYROIDISM; INFLUENZA; INJECTION SITE ERYTHEMA; INSOMNIA; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MOOD DISORDER; MOUTH ULCER; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; PRIORITY JOURNAL; RASH; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; YOUNG ADULT;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LACTAMS; MALE; MIDDLE AGED; MUTATION; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RITONAVIR; RNA, VIRAL; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84893454551     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01515-13     Document Type: Article

References (34)

1. World Health Organizations. 2012. Hepatitis C fact sheet no. 164. World Health Organization, Geneva, Switzerland. http://www.who.int/mediacentre/ factsheets/fs164/en/index.html. Accessed 11 September 2012.
2. Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, Colombo M, Delarocque-Astagneau E, Dusheiko G, Esmat G, Esteban R, Goldberg D, Gore C, Lok AS, Manns M, Marcellin P, Papatheodoridis G, Peterle A, Prati D, Piorkowsky N, Rizzetto M, Roudot-Thoraval F, Soriano V, Thomas HC, Thursz M, Valla D, van Damme P, Veldhuijzen IK, Wedemeyer H, Wiessing L, Zanetti AR, Janssen HL. 2011. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J. Viral Hepat. 18(Suppl 1):1-16. http://dx.doi.org/10.1111/ j.1365-2893.2011.01499.x.
3. Ghany MG, Strader DB, Thomas DL, Seeff LB. 2009. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49:1335-1374. http://dx.doi.org/10.1002/hep.22759.
4. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitisCvirus infection. N. Engl. J. Med. 347:975-982. http://dx.doi.org/10.1056/NEJMoa020047.
5. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, Mc-Cone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, Study Team IDEAL. 2009. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 361:580-593. http://dx.doi.org/10.1056/NEJMoa0808010.
6. Hadziyannis SJ, Sette H, Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. 2004. Peginterferon-+2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140:346-355. http://dx.doi.org/10.7326/0003-4819-140-5- 200403020-00010.
7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965. http://dx.doi.org/10.1016/S0140-6736(01)06102-5.
8. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. 2011. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54:1433-1444. http://dx.doi.org/10.1002/hep.24641.
9. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Mullhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. 2011. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364: 2417-2428. http://dx.doi.org/10.1056/ NEJMoa1013086.
10. Poordad F, McCone Jr, Bacon JBR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP, SPRINT-2 Investigators. 2011. Boceprevir for untreated chronicHCVgenotype 1 infection. N. Engl. J. Med. 364:1195-1206. http://dx.doi.org/10.1056/NEJMoa1010494.
11. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. 2011. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364:2405-2416. http://dx.doi.org/10.1056/NEJMoa1012912.
12. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F. 2011. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 365:1014-1024. http://dx.doi.org/10.1056/NEJMoa1014463.
13. Vierling JM, Flamm SL, Gordon SC, Lawitz EJ, Bronowicki JP, Davis M, Yoshida EM, Pedicone LD, Deng W, Treitel MA, Brass CA, Albrecht JK, Jacobson IM. 2011. Efficacy of boceprevir in prior null responders to peginterferon/ ribavirin: the PROVIDE study. Hepatology 54(Suppl 1): 796A-797A. http://dx.doi.org/10.1002/hep.24666.
14. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. 2011. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364:1207-1217. http://dx.doi.org/10.1056/ NEJMoa1009482.
15. Weiss JJ, Alcorn MC, Rabkin JG, Dieterich DT. 2012. The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice. J. Hepatol. 56:503-504. http://dx.doi.org/10.1016/j.jhep.2011.05.014.
16. Gordon SC, Lawitz EJ, Bacon BR, Sulkowski MS, Yoshida EM, Davis M, Boparai N, Sniukiene V, Burroughs M, Brass CA, Albrecht JK, Reddy KR. 2011. Adherence to assigned dosing regimen and sustained virologic response among hepatitis C genotype 1 treatment-naive and PEG/ ribavirin treatment-failures treated with boceprevir plus peginterferon alfa-2b/ribavirin. J. Hepatol. 54(Suppl 1):S173-S174. http://dx.doi.org/10.1016/S0168-8278(11)60430-3.
17. Poordad F, Dieterich D. 2012. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J. Viral Hepat. 19:449-464. http://dx.doi.org/10.1111/j.1365-2893.2012.01617.x.
18. Seiwert SD, Andrews SW, Jiang Y, Serebryany V, Tan H, Kossen K, Rajagopalan PT, Misialek S, Stevens SK, Stoycheva A, Hong J, Lim SR, Qin X, Rieger R, Condroski KR, Zhang H, Do MG, Lemieux C, Hingorani GP, Hartley DP, Josey JA, Pan L, Beigelman L, Blatt LM. 2008. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob. Agents Chemother. 52:4432-4441. http://dx.doi.org/10.1128/AAC.00699-08.
19. Gane EJ, Rouzier R, Stedman C, Wiercinska-Drapalo A, Horban A, Chang L, Zhang Y, Sampeur P, Nájera I, Smith P, Shulman NS, Tran JQ. 2011. Antiviral activity, safety, and pharmacokinetics of danoprevir/ ritonavir plus PEG-IFN alpha-2a/RBV in hepatitis C patients. J. Hepatol. 55:972-979. http://dx.doi.org/10.1016/j.jhep.2011.01.046.
20. Reddy MB, Chen Y, Haznedar JO, Fretland J, Blotner S, Smith P, Tran JQ. 2012. Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study. Clin. Pharmacokinet. 51:457-465. http://dx.doi.org/10.2165/11599700-000000000-00000.
21. Everson GT, Cooper C, Hézode C, Shiffman ML, Yoshida EM, Beltran-Jaramillo T, Andreone P, Bruno S, Ferenci P, Zeuzem S, Brunda M, Le Pogam S, Nájera I, Zhou J, Navarro MT, Voulgari A, Shulman NS, Yetzer ES. 2012. High SVR24 rates with 12 to 24 weeks of ritonavirboosted danoprevir plus Peg-IFNalfa-2a (40KD)/RBV inHCVgenotype 1 or 4 patients in the DAUPHINE study. Hepatology 56(Suppl 1):552A. http://dx.doi.org/10.1002/hep.26040.
22. Goelzer P, Morcos PN, Tran JQ, Wen B, Shulman NS, Brennan BJ, Hammond J, Singer T, Smith P. 2012. Coadministration of ritonavir with theHCVprotease inhibitor danoprevir substantially reduces reactive metabolite formation both in vitro and in vivo. Hepatology 56(Suppl 1): 580A. http://dx.doi.org/10.1002/hep. 26040.
23. Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, Hézode C, Hirschfield G, Jacobson I, Nikitin I, Pockros P, Poordad F, Lenz O, Peeters M, Sekar V, De Smedt G, Beumont-Mauviel M. 2012. TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon/ ribavirin treatment: final SVR24 results of the ASPIRE trial. J. Hepatol. 56(Suppl 2):S1-S2. http://dx.doi.org/10.1016/S0168-8278(12)60016-6.
24. Sulkowski MS, Bourlière M, Bronowicki J-P, Asselah T, Pawlotsky JM, Shafran SD, Pol S, Mauss S, Larrey D, Datsenko Y, Stern JO, Kukolj G, Scherer J, Nehmiz G, Steinmann GG, Böcher WO. 2013. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology 57:2155-2163. http://dx.doi.org/10.1002/hep.26386.
25. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD. 2007. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132:1767-1777. http://dx.doi.org/10.1053/j.gastro.2007.02.037.
26. Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, Ipe D, Morcos PN, Baher L, Nájera I, Chu T, Lopatin U, Berrey MM, Bradford W, Laughlin M, Shulman NS, Smith PF. 2010. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376:1467-1475. http://dx.doi.org/10.1016/S0140- 6736(10)61384-0.
27. Feld JJ, Jacobson IM, Jensen DM, Foster GR, Pol S, Tam E, Berak H, Vierling JM, Tavel J, Navarro MT, Shahdad S, Kulkarni R, Le Pogam S, Nájera I, Lim CY, Shulman NS, Yetzer ES. 2012. Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine (MCB) and ribavirin with or without peginterferon alfa-2a (40KD) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study. Hepatology 56(Suppl 1):231A-232A. http://dx.doi.org/10.1002/hep.26040.
28. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C. 2012. Preliminary study of two antiviral agents for hepatitis C genotype. N. Engl. J. Med. 366:216-224. http://dx.doi.org/10.1056/NEJMoa1104430.
29. Lok AS, Gardiner DF, Hézode C, Lawitz E, Bourlière M, Everson GT, Marcellin P, Rodriguez-Torres M, Pol S, Serfaty L, Eley T, Huang S, Wind-Rotolo M, McPhee F, Grasela DM, Pasquinelli C. 2012. Sustained virologic response in chronic HCV genotype (GT) 1-infected null responders with combination of daclatasvir (DCV; NS5A inhibitor) and asunaprevir (ASV; NS3 inhibitor) with or without peginterferon alfa-2a/ ribavirin (PEG/RBV) (oral presentation 79). Hepatology 56(Suppl 1): 230A-231A. http://dx.doi.org/10.1002/ hep.26040.
30. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson D, Zeuzem S, Everson GT, Kwo P, Foster GR, Sulkowski M. 2012. A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and ribavirin achieves SVR12 rates (observed data) of 99% in treatment-naive patients and 93% in prior null responders withHCVgenotype 1 infection. Hepatology 56(Suppl 1):1515A-1516A. http://dx.doi.org/10.1002/hep.26040.
31. Abbott Laboratories. 2012. Norvir (ritonavir) package insert. Abbott Laboratories, North Chicago, IL 60064.
32. Perelson AS, Deeks SG. 2011. Drug effectiveness explained: the mathematics of antiviral agents for HIV. Sci. Transl. Med. 13:91ps30. http://dx.doi.org/10.1126/scitranslmed.3002656.
33. Marcellin P, Cooper C, Balart LA, Larrey DG, Box TD, Yoshida E, Lawitz E, Buggisch P, Ferenci P, Weltman M, Labriola-Tompkins E, Le Pogam S, Nájera I, Thomas D, Hooper G, Shulman NS, Zhang Y, Navarro MT, Lim CY, Brunda M, Terrault N, Yetzer ES. 2013. Randomized controlled trial of danoprevir plus peginterferon alfa-2a/ ribavirin in treatment-naive HCV genotype 1 patients. Gastroenterology 145:790-800. http://dx.doi.org/10.1053/j.gastro.2013. 06.051.
34. Tujios S, Fontana RJ. 2011. Mechanisms of drug-induced liver injury: from bedside to bench. Nat. Rev. Gastroenterol. Hepatol. 8:202-211. http://dx.doi.org/10.1038/nrgastro.2011.22.